GET DAILY SIGNALSPing An Biomedical (PASW) Declines -19% Over 30 Days After Reverse Split
Key Takeaways
- Ping An Biomedical (PASW) shares declined roughly 19% on a split-adjusted basis over the trailing 30 days, falling from about $5.07 to about $4.10.
- The slide coincided with the execution of a 1-for-40 reverse stock split on October 23, 2026, intended to restore compliance with Nasdaq's $1.00 minimum bid price rule.
- A non-binding letter of intent to acquire three oncology-related patents for $2 million to $2.5 million drew attention but has not yet produced any biomedical revenue.
- Over the trailing quarter, PASW has fallen roughly 17%, extending a longer downtrend tied to shrinking apparel revenue and widening net losses.
- Thin liquidity and a sharply reduced share float have amplified volatility, producing unusually wide intraday trading ranges around the split.
- The company remains a micro-cap in transition, pivoting from apparel supply-chain management toward healthcare and biomedical technology.
- For additional detail, review PASW's Price Targets, Earnings, and Forecast on dedicated analysis pages.
- Explore Trending AI Robots to see how AI-driven trading strategies are positioning across the market.
Company Background and Current Position
Ping An Biomedical Co., Ltd., formerly Majestic Ideal Holdings Ltd., is a Cayman Islands-incorporated, Hong Kong-headquartered holding company. Through its PRC subsidiary NewBrand, it operates as a one-stop supply chain management provider for the apparel industry, covering market trend analysis, product design and development, raw material sourcing, production and quality control, and logistics. The business breaks down into two segments—yarns (including cashmere, merino wool, and cotton) and finished garments—serving customers across China, Hong Kong, Cambodia, and Europe.
Following a leadership change and rebranding in late 2025 under Chief Executive Officer Pijun Liu, the company has been shifting focus toward healthcare and biomedical technology. Even with the new name, it has not yet reported meaningful biopharma revenue. With a market capitalization around $16 million and roughly seven employees, PASW stands as a thinly traded micro-cap that draws interest mainly for its turnaround story, capital-structure moves, and Nasdaq compliance status. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Recent Stock Performance: 30 Days and the Quarter
On a split-adjusted basis, PASW shares have declined approximately 19% over the trailing 30 days, moving from a close near $5.07 to around $4.10. The path was not steady; trading around the October 23 reverse split produced wide swings, with the stock reaching an intraday high above $6 and a low near $3 on the split-effective date before settling lower.
The quarterly view looks similar. Measured from the late-July level of roughly $4.93, shares have declined about 17%. This continues a broader multi-month downtrend, as the stock entered the period under pressure from weakening financial results. The reverse split, while mechanically lifting the nominal share price, did not change underlying fundamentals. The split-adjusted decline over both the 30-day and three-month windows reflects real price depreciation rather than the corporate action alone.
Key Drivers Behind the Last 30 Days
The main catalyst over the last 30 days was the company's 1-for-40 reverse stock split, effective October 23, 2026. The board approved the ratio on August 6, 2026, and the company announced the effective date shortly before execution. The consolidation reduced Class A shares from approximately 112.9 million to about 2.8 million and Class B shares from roughly 12.25 million to about 306,000, while the ticker remained PASW.
The reverse split addressed a Nasdaq minimum bid price deficiency notice received in late November 2025, after the stock had traded below $1.00 for an extended period. Pre-split, PASW was trading around $0.12, and the 1-for-40 consolidation aimed to lift the quote above Nasdaq's $1.00 threshold. Reverse splits of this size are often seen by the market as a sign of financial strain, and the stock declined on a split-adjusted basis in the sessions surrounding the change.
A second development was the October 22, 2026 announcement of a non-binding letter of intent to acquire three tumor cell-related medical technology patents from Future Biotechnology Group for $2 million to $2.5 million. Because the transaction remains subject to due diligence and a definitive agreement, and is not expected to generate near-term revenue, it contributed to speculative trading rather than a lasting re-rating. Thin liquidity and the sharply reduced float amplified volatility throughout the period.
Drivers of Performance Over the Last Quarter
Over the trailing quarter, PASW's decline reflected a mix of fundamental weakness and structural uncertainty. The company's core apparel supply-chain business has been shrinking, with fiscal 2025 revenue declining approximately 61% year over year and net losses widening sharply. There is no meaningful biomedical revenue yet in the financials, leaving the company dependent on the turnaround narrative rather than demonstrated operating results.
The quarter also included a series of capital-structure changes, such as the introduction of Class B shares with enhanced voting rights, an increase in authorized share capital, and the eventual 1-for-40 consolidation. These actions, together with the Nasdaq compliance overhang, kept sentiment cautious. Earlier in 2026, the company disclosed new investment and a channel cooperation agreement targeting RMB 500 million in cumulative sales over three years, but these initiatives have yet to translate into reported revenue. Against this backdrop, episodic high-volume spikes in late July and late August gave way to renewed selling pressure, leaving the stock lower across the three-month window.
Factors to Watch Going Forward
Several factors are likely to shape PASW shares in the months ahead. First, investors will monitor whether the post-split price holds above Nasdaq's $1.00 minimum bid requirement; the company has scheduled an extraordinary general meeting on October 29, 2026 to ratify the reverse split and authorize additional, conditional reverse splits should the price fall below $1.00 again, introducing further dilution and compliance risk.
Second, the oncology patent acquisition remains at the letter-of-intent stage; execution of a definitive agreement—or the absence of one—could become a catalyst. Third, any evidence that the biomedical pivot is generating actual revenue, rather than announcements alone, will be closely watched alongside the health of the shrinking apparel segment. Finally, given the very small post-split float, liquidity risk and elevated volatility are likely to persist, making price action highly sensitive to news flow and limited trading volume. From what I see, this is important because the small float can magnify moves on limited volume.
Exploring AI Tools in My Research Process
In my analysis of names like PASW, I occasionally turn to Tickeron’s AI Trend Prediction Engine to review potential patterns and signals across similar micro-cap situations. It provides a structured way to cross-check price history and volatility metrics without replacing core fundamental review. This step helps confirm whether recent moves align with broader algorithmic observations in the space.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
PASW in +3.28% Uptrend, rising for three consecutive days on October 13, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where PASW advanced for three days, in 38 of 45 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
PASW may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 8 of 8 cases where PASW's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on October 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PASW as a result. In 18 of 19 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for PASW turned negative on October 23, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 8 similar instances when the indicator turned negative. In 8 of the 8 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
PASW moved below its 50-day moving average on October 23, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for PASW crossed bearishly below the 50-day moving average on September 25, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 2 of 2 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PASW declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for PASW entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 7 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.343) is normal, around the industry mean (1.842). P/E Ratio (-15.958) is within average values for comparable stocks, (29.795). PASW's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (3.950). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. PASW's P/S Ratio (4.409) is slightly higher than the industry average of (1.630).
The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. PASW’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PASW’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 100, placing this stock worse than average.
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Textiles
Advertisement